Janus Henderson Group PLC Has $73.60 Million Stake in HealthEquity, Inc. (NASDAQ:HQY)

Janus Henderson Group PLC lowered its stake in shares of HealthEquity, Inc. (NASDAQ:HQY) by 18.4% in the third quarter, HoldingsChannel reports. The institutional investor owned 899,240 shares of the company’s stock after selling 202,233 shares during the period. Janus Henderson Group PLC’s holdings in HealthEquity were worth $73,604,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. International Assets Investment Management LLC bought a new position in shares of HealthEquity during the 2nd quarter valued at $35,000. Paladin Wealth LLC bought a new position in HealthEquity in the 3rd quarter worth $39,000. GAMMA Investing LLC raised its holdings in HealthEquity by 114.8% in the 2nd quarter. GAMMA Investing LLC now owns 595 shares of the company’s stock worth $51,000 after acquiring an additional 318 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in HealthEquity in the 2nd quarter worth $73,000. Finally, 1620 Investment Advisors Inc. bought a new position in HealthEquity in the 3rd quarter worth $112,000. Institutional investors and hedge funds own 99.55% of the company’s stock.

HealthEquity Price Performance

Shares of HQY stock opened at $100.85 on Friday. HealthEquity, Inc. has a 1 year low of $62.10 and a 1 year high of $105.82. The firm’s 50 day moving average is $92.02 and its 200-day moving average is $83.44. The firm has a market capitalization of $8.81 billion, a price-to-earnings ratio of 84.04, a PEG ratio of 1.59 and a beta of 0.55. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51.

HealthEquity (NASDAQ:HQY) last issued its earnings results on Tuesday, September 3rd. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.50 by $0.16. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. The firm had revenue of $299.93 million during the quarter, compared to the consensus estimate of $284.48 million. Sell-side analysts forecast that HealthEquity, Inc. will post 2.27 EPS for the current fiscal year.

Insider Activity

In related news, Director Robert W. Selander sold 8,250 shares of the firm’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total transaction of $684,585.00. Following the transaction, the director now directly owns 54,719 shares of the company’s stock, valued at approximately $4,540,582.62. This trade represents a 13.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Frank Corvino sold 1,039 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total transaction of $99,847.90. Following the transaction, the director now directly owns 3,784 shares in the company, valued at approximately $363,642.40. This represents a 21.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,536 shares of company stock worth $884,517 over the last quarter. 2.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts recently commented on HQY shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $92.00 target price on shares of HealthEquity in a report on Wednesday, September 4th. The Goldman Sachs Group began coverage on shares of HealthEquity in a report on Friday, November 15th. They issued a “neutral” rating and a $108.00 target price on the stock. Bank of America boosted their price objective on shares of HealthEquity from $100.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Barrington Research boosted their price objective on shares of HealthEquity from $105.00 to $120.00 and gave the stock an “outperform” rating in a report on Monday. Finally, JMP Securities restated a “market outperform” rating and set a $105.00 price objective on shares of HealthEquity in a report on Wednesday, September 4th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $109.64.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.